Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELI LILLY & CoLLY · Entity 2794 | EVP, President LLY Imm | November 07, 2025 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELI LILLY & Co
Report date November 07, 2025 · Filed September 04, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,045.237 |
Reported balance
Holding disclosure · report date 2025-11-07 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 7,045.237 F1: Corrects the number of shares previously reported to account for additional shares that were unintentionally omitted from the original Form 3 filing, and subsequent Forms 4. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2026-02-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-11-07 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance Not disclosed F2: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2026-11-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-11-07 · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · Balance Not disclosed F2: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2027-02-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-11-07 · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · Balance Not disclosed F2: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2028-02-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-11-07 · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · Balance Not disclosed F2: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Corrects the number of shares previously reported to account for additional shares that were unintentionally omitted from the original Form 3 filing, and subsequent Forms 4.
F2: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2026 Filed Feb 18, 2026 21:19 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0002096888-26-000004 · wk-form4_1771449581.xml · derivative · entry 3 Brown Adrienne S · CIK 0002096888 · EVP, President LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 391 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 21:19 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 169.966 | $1,040.00 | $176,764.64 |
DisclosureSEC source: 0002096888-26-000004 · wk-form4_1771449581.xml · nonDerivative · entry 2 Brown Adrienne S · CIK 0002096888 · EVP, President LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,142.342 Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 21:19 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0002096888-26-000004 · wk-form4_1771449581.xml · nonDerivative · entry 1 Brown Adrienne S · CIK 0002096888 · EVP, President LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,312.308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:12 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 1,196.308 | $1,044.67 | $1,249,747.08 |
DisclosureSEC source: 0002096888-26-000002 · wk-form4_1770844352.xml · nonDerivative · entry 1 Brown Adrienne S · CIK 0002096888 · EVP, President LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,921.308 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.